Alzheimer's phenotypes induced by overexpression of human presenilin 2 mutant proteins stimulate significant changes in key factors of glucose metabolism

Molecular Medicine Reports

Volumn 7, Issue 5, 2013, Pages 1571-1578

  Lee, Young Ju ^a   Kim, Ji Eun ^a   Hwang, In Sik ^a   Kwak, Moon Hwa ^a   Lee, Jae Ho ^a   Jung, Young Jin ^a   An, Beum Soo ^a   Kwon, Hyeog Soong ^a   Kim, Byoung Chul ^a   Kim, Seon Jong ^a   Kim, Joo Man ^a   Hwang, Dae Youn ^a  

^a Pusan National University   (South Korea)

Author keywords

AKT; Glucose transporter; GSK; Insulin; Insulin receptor; Presenilin 2

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; GAMMA SECRETASE; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3BETA; INSULIN; INSULIN RECEPTOR; NEURON SPECIFIC ENOLASE; PRESENILIN 2; PROTEIN KINASE B; SOMATOMEDIN RECEPTOR; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN METABOLISM; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; GLUCOSE METABOLISM; MOUSE; NEUROPATHOLOGY; NONHUMAN; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; GLUCOSE; GLUCOSE TRANSPORT PROTEINS, FACILITATIVE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; INSULIN; MICE; MICE, TRANSGENIC; MUTANT PROTEINS; PHENOTYPE; PHOSPHOPYRUVATE HYDRATASE; PHOSPHORYLATION; PRESENILIN-2; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, IGF TYPE 1; RECEPTOR, INSULIN; SIGNAL TRANSDUCTION;

MUS; MUS MUSCULUS;

EID: 84875977924     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2013.1404     Document Type: Article

References (41)

1. Gsell W, Moll G, Sofic E and Riederer P: Cholinergic and monoaminergic neurotransmitter systems in patients with Alzheimer's disease and senile dementia of Alzheimer type: a clinical evaluation. In: Dementias-neurochemistry, neuropathology, neuroimaging, neuropsychology and genetics. Maurer K (ed). Braunschweig, Vieweg, pp25-51, 1993.
2. Hoyer S: Senile dementia and Alzheimer's disease. Brain blood flow and metabolism. Prog Neuropsychopharmacol Biol Psychiatry 10: 447-478, 1986.
3. Hoyer S, Oesterreich K and Wanger O: Glucose metabolism as the site of the primary abnormality in early-onset dementia of Alzheimer type? J Neurol 235: 143-148, 1988.
4. Hoyer S, Nitsch R and Oesterreich K: Predominant abnormality in cerebral glucose utilization in late-onset dementia of the Alzheimer type: a cross-sectional comparison against advanced late-onset and incipient early-onset cases. J Neural Transm Park Dis Dement Sect 3: 1-14, 1991.
5. Bigl M, Apelt J, Eschrich K and Schliebs R: Cortical glucose metabolism is altered in aged transgenic Tg2576 mice that demonstrate Alzheimer plaque pathology. J Neural Transm 110: 77-94, 2003.
6. Mooradian AD, Chung HC and Shah GN: Glut-1 expression in the cerebral of patients with Alzheimer's disease. Neurobiol Aging 18: 469-474, 1997.
7. Simpson IA, Chundu KR, Davies-Hill T, Honer WG and Davies P: Decreased concentrations of Glut1 and Glut3 glucose transporters in the brains of patients with Alzheimer's disease. Ann Neurol 35: 546-551, 1994.
8. Baskin DG, Wilcox BJ, Figlewicz DP and Dorsa DM: Insulin and insulin-like growth factors in the CNS. Trends Neurosci 11: 107-111, 1988.
9. Wozniak M, Rydzewski B, Baker SP and Raizada MK: The cellular and physiological actions of insulin in the central nervous system. Neurochem Int 22: 1-10, 1993.
10. Harvankova J, Schmerchel D, Roth J and Brownstein M: Identification of insulin in rat brain. Proc Natl Acad Sci USA 75: 5737-5741, 1978.
11. Devasker SU, Giddings SJ, Rajakumar PA, Carnaghi LR, Menon RK and Zahm DS: Insulin gene expression and insulin synthesis in mammalian neuronal cells. J Biol Chem 269: 8445-8454, 1994.
12. Hoyer S, Prem L, Sorbi S and Amsucci L: Stimulation of glycolytic key enzymes in cerebral cortex by insulin. Neuroreport 4: 991-993, 1993.
13. de Pablo F and de la Rosa E: The developing CNS: a scenario for the action of proinsulin, insulin and insulin-like growth factors. Trends Neurosci 18: 143-150, 1995.
14. Calissano P, Ciotti MT, Battistini L, Zona C, Angelini A, Merlo D and Mercanti D: Recombination insulin-like growth factor I exerts a trophic action and confers glutamate sensitivity on glutamate-resistant cerebellar cells. Proc Natl Acad Sci USA 90: 8752-8756, 1993.
15. Quirion R, Araujo DM, Lapehak PA, Seto D and Chabot JG: Growth factors and lymphokines: modulators of cholinergic neuronal activity. Can J Neurol Sci 18: 390-393, 1991.
16. Sun XJ, Rothenberg P, Kahn CR, Backer JM, Araki E, Wilden PA, Cahill DA, Goldstein BJ and White MF: Structure of the insulin receptor substrate ISR-1 defines a unique signal transduction protein. Nature 352: 73-77, 1991.
17. White MF and Kahn CR: The insulin signaling system. J Biol Chem 269: 1-4, 1994.
18. Frolich L, Blum-Degen D, Bernstein HG, Engelsberger S, Humrich J, Laufer S, Muschner D, Thalheimer A, Turk A, Hoyer S, Zochling R, Boissle KW, Jellinger K and Riederer P: Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J Neural Transm 105: 423-438, 1998.
19. Hwang DY, Chae KR, Kang TS, Hwang JH, Lim CH, Kang HK, Goo JS, Lee MR, Lim HJ, Min SH, Cho JY, Hong JT, Song CW, Paik SG, Cho JS and Kim YK: Alterations in behavior, amyloid β-42, caspase-3, and Cox-2 in mutant PS2 transgenic mouse model of Alzheimer's disease. FASEB J 16: 805-813, 2002.
20. Hwang DY, Cho JS, Oh JH, Shim SB, Jee SW, Lee SH, Seo SJ, Lee SK, Lee SH and Kim YK: Differentially expressed genes in transgenic mice carrying human mutant presenilin-2 (N141I): correlation of selenoprotein M with Alzheimer's disease. Neurochem Res 30: 1009-1019, 2005.
21. Garofalo RS, Orena SJ, Rafidi K, Torchia AJ, Stock JL, Hildebrandt AL, Coskran T, Black SC, Brees DJ, Wicks JR, McNeish JD and Coleman KG: Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB beta. J Clin Invest 112: 197-208, 2003.
22. Meijer L, Flajolet M and Greengard P: Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol Sci 25: 471-480, 2004.
23. Boyt AA, Taddei TK, Hallmayer J, Helmerhorst E, Gandy SE, Craft S and Martins RN: The effect of insulin and glucose on the plasma concentration of Alzheimer's amyloid precursor protein. Neuroscience 95: 727-734, 2000.
24. Meier-Ruge WA and Bertoni-Freddari C: Pathogenesis of decreased glucose turnover and oxidative phosphorylation in ischemic and trauma-induced dementia of the Alzheimer type. Ann N Y Acad Sci 826: 229-241, 1997.
25. Hoyer S: Brain glucose and energy metabolism abnormalities in sporadic Alzheimer disease. Causes and consequences: an update. Exp Gerontol 35: 1363-1372, 2000.
26. Hoyer S: The brain insulin signal transduction system and sporadic (type II) Alzheimer disease: an update. J Neural Transm 109: 341-360, 2002.
27. Oyama F, Sawamura N, Kobayashi K, Morishima-Kawashima M, Kuramochi T, Ito M, Tomita T, Maruyama K, Saido TC, Iwatsubo T, Capell A, Walter J, Grunberg J, Ueyama Y, Haass C and Ihara Y: Mutant presenilin 2 transgenic mouse: effect on an age-dependent increase of amyloid beta-protein 42 in the brain. J Neurochem 71: 313-322, 1998.
28. Polonsky KS and Rubenstein AH: C-peptide as a measure of the secretion an hepatic extraction of insulin. Pitfalls and limitations. Diabetes 33: 486-494, 1984.
29. Kurochkin IV and Goto S: Alzheimer's beta-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme. FEBS Lett 345: 33-37, 1994.
30. Authier F, Posner BI and Bergeron JJ: Insulin-degrading enzyme. Clin Invest Med 19: 149-160, 1996.
31. Perez A, Morelli L, Cresto JC and Castano EM: Degradation of soluble amyloid beta-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains. Neurochem Res 25: 247-255, 2000.
32. Vekrellis K, Ye Z, Qui WQ, Walsh D, Hartley D, Cheseneau V, Rosner MR and Selkoe DJ: Neurons regulate extracellular levels of amyloid-protein via proteolysis by insulin-degrading enzyme. J Neurosci 20: 1657-1665, 2000.
33. Henneberg N and Hoyer S: Short-term or long-term intracerebroventricular (i.c.v) infusion of insulin exhibits a discrete anabolic effect on cerebral energy metabolism in the rat. Neurosci Lett 175: 153-156, 1994.
34. De Keyser J, Wilczak N and Goosens A: Insulin-like growth factor-1 receptor densities in human frontal cortex and white matter during aging, in Alzheimer's disease, and in Huntington's disease. Neurosci Lett 172: 93-96, 1994.
35. Crew FT, McElhaney R, Freund G, Ballinger WE Jr and Raizada MK: Insulin-like growth factor I receptor binding in brains of Alzheimer's and alcoholic patients. J Neurochem 58: 1205-1210, 1992.
36. Stein TD and Johnson JA: Lack of neurodegeneration in transgenic mice overexpressing mutant amyloid precursor protein is associated with increased level of transthyretin and the activation of cell survival pathways. J Neurosci 22: 7380-7388, 2002.
37. Craft S, Dagogo-Jack SE, Wiethop BV, Murphy C, Nevins R, Fleschman S, Rice V, Newcomber JW and Cryer PE: Effects of hyperglycemia on memory and hormone levels in dementia of the Alzheimer type: a longitudinal study. Behav Neurosci 107: 926-940, 1993.
38. Manning CA, Ragozzino ME and Gold PE: Glucose enhancement of memory in patients with probable senile dementia of the Alzheimer's type. Neurobiol Aging 14: 523-528, 1993.
39. Harr SD, Simonian NA and Hyman BT: Functional alterations in Alzheimer's disease: decreased glucose transporter 3 immunoreactivity in the perforant pathway terminal zone. J Neuropathol Exp Neurol 54: 38-41, 1995.
40. Sivitz WS, DeSautel PS and Pessin JE: Regulation of the glucose transporter in developing rat brain. Endocrinology 124: 1875-1880, 1989.
41. Craft S, Asthana S, Cook DG, Baker LD, Cherrier M, Purganan K, Wait C, Petrova A, Latendresse S, Watson GS, Newcomer JW, Schellenberg GD and Krohn AJ: Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype. Psychoneuroendocrinology 28: 809-822, 2003.